DYN vs. RNA, DRNA, ARWR, AMPH, PTGX, CTLT, ROIV, ELAN, ASND, and LEGN
Should you be buying Dyne Therapeutics stock or one of its competitors? The main competitors of Dyne Therapeutics include Avidity Biosciences (RNA), Dicerna Pharmaceuticals (DRNA), Arrowhead Pharmaceuticals (ARWR), Amphastar Pharmaceuticals (AMPH), Protagonist Therapeutics (PTGX), Catalent (CTLT), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Ascendis Pharma A/S (ASND), and Legend Biotech (LEGN). These companies are all part of the "medical" sector.
Dyne Therapeutics (NASDAQ:DYN) and Avidity Biosciences (NASDAQ:RNA) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, community ranking, media sentiment and earnings.
Dyne Therapeutics has a net margin of 0.00% compared to Avidity Biosciences' net margin of -2,103.78%. Avidity Biosciences' return on equity of -37.98% beat Dyne Therapeutics' return on equity.
Avidity Biosciences has higher revenue and earnings than Dyne Therapeutics. Avidity Biosciences is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.
Dyne Therapeutics has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.Comparatively, Avidity Biosciences has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500.
Avidity Biosciences received 119 more outperform votes than Dyne Therapeutics when rated by MarketBeat users. However, 75.00% of users gave Dyne Therapeutics an outperform vote while only 64.62% of users gave Avidity Biosciences an outperform vote.
Dyne Therapeutics presently has a consensus target price of $40.78, indicating a potential upside of 32.40%. Avidity Biosciences has a consensus target price of $41.33, indicating a potential upside of 57.58%. Given Avidity Biosciences' higher possible upside, analysts plainly believe Avidity Biosciences is more favorable than Dyne Therapeutics.
In the previous week, Dyne Therapeutics had 10 more articles in the media than Avidity Biosciences. MarketBeat recorded 20 mentions for Dyne Therapeutics and 10 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 0.78 beat Dyne Therapeutics' score of 0.58 indicating that Avidity Biosciences is being referred to more favorably in the news media.
96.7% of Dyne Therapeutics shares are owned by institutional investors. 20.8% of Dyne Therapeutics shares are owned by insiders. Comparatively, 3.7% of Avidity Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Dyne Therapeutics beats Avidity Biosciences on 10 of the 18 factors compared between the two stocks.
Get Dyne Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DYN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dyne Therapeutics Competitors List
Related Companies and Tools
